Address: 2405 North Fraser Street Georgetown, SC 29442 Phone: (843) 545-5600
Visit the Georgetown Hospital System website Get directions to Georgetown Hospital System Participation in the following CTN Cooperative Group studies:
CTO #100899 - NSABP B-39: Breast Program A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0,I, or II Breast Cancer
CTO #101183 - NSABP B-40: Breast Program A Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect in Pathologic Complete Response (pCD) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimes CTO #101171 - Tailor-x PACCT-1: Breast Program Program for the Assistance of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The Tailor-X Trial CTO #101184 - ECOG 5204: Gastrointestinal Program Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin Vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pro-operative Chemoradiation CTO #101185 - ECOG 5202: Gastorintestinal Program A Randomized Phase III Study Comparing 5-FU, Leucovorin, and Oxaliplatin Vs. 5-FU, Leucovorin, Oxaliplatin, and Bevacizumab in Patients with Stage II Colon Cancer at High Risk to Determine Prospectively to Prognostic value of Molecular Markers CTO #101186 - CALGB C80405: Gastrointestinal Program A Phase II Trial of Irinotecan, 5FU, Leucovorin or Oxaliplatin, 5FU, Leucovorin with Bevacizumab or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Color or Rectum |